Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 5/20 | 0.37 |
| ▸ | NCF1 | P14598 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 4/20 | 0.35 |
| ▸ | CA1 | P00915 | 4/20 | 0.35 |
| ▸ | CA4 | P22748 | 4/20 | 0.35 |
| ▸ | CA9 | Q16790 | 4/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | ENO1 | P06733 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL422917 | 1.00 | GLP1R (0.38) | GLP1RSMN1; SMN2MEN1KMT2ACA2 | |
| SCHEMBL16943973 | 1.00 | GLP1R (0.38) | GLP1RSMN1; SMN2MEN1KMT2ACA2 | |
| SCHEMBL964367 | 1.00 | GLP1R (0.38) | GLP1RSMN1; SMN2MEN1KMT2ACA2 | |
| SCHEMBL1257485 | 0.97 | GLP1R (0.41) | GLP1RSMN1; SMN2MEN1KMT2ACA2 | |
| SCHEMBL30466662 | 0.97 | GLP1R (0.41) | GLP1RSMN1; SMN2MEN1KMT2ACA2 | |
| SCHEMBL20017289 | 0.93 | MEN1 (0.41) | GLP1RSMN1; SMN2MEN1KMT2ACA2 | |
| SCHEMBL2743010 | 0.91 | SMN1; SMN2 (0.43) | GLP1RSMN1; SMN2MEN1KMT2ACA2 | |
| SCHEMBL14453741 | 0.90 | TSHR (0.43) | GLP1RSMN1; SMN2TSHRRECQL | |
| SCHEMBL24040332 | 0.89 | MEN1 (0.41) | GLP1RSMN1; SMN2MEN1KMT2ACA2 | |
| SCHEMBL24518424 | 0.87 | SMN1; SMN2 (0.36) | GLP1RSMN1; SMN2MEN1KMT2ACA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3620465-B1 | IMPROVED METHODS FOR GENERATION, LABELING AND USE OF MHC MULTIMERS | DAKO DENMARK AS (DK) | 2025-02-19 | — | — | EP | disclosed |
| US-20240150431-A1 | MHC Multimers, Methods for Their Generation, Labeling and Use | DAKO DENMARK APS (DK) | 2024-05-09 | — | — | US | disclosed |
| US-20230340039-A1 | NPY2 RECEPTOR AGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2023-10-26 | — | — | US | disclosed |
| US-20230270867-A1 | CONJUGATE IN WHICH FL118 DRUG IS LINKED TO ACID-SENSITIVE LINKER, AND IMMUNOCONJUGATE USING SAME | PINOTBIO, INC. (KR) | 2023-08-31 | — | — | US | disclosed |
| EP-4192853-A1 | SOLUBLE NPY2 RECEPTOR AGONISTS | Boehringer Ingelheim International GmbH (DE) | 2023-06-14 | — | — | EP | disclosed |
| EP-4058047-A1 | NPY2 RECEPTOR AGONISTS | Boehringer Ingelheim International GmbH (DE) | 2022-09-21 | — | — | EP | disclosed |
| WO-2021094259-A1 | NPY2 RECEPTOR AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-05-20 | — | — | WO | disclosed |
| US-20210139548-A1 | NPY2 RECEPTOR AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-05-13 | — | — | US | disclosed |
| US-20190112348-A1 | PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES | NOVO NORDISK AS (DK) | 2019-04-18 | — | — | US | disclosed |
| US-10259856-B2 | Protease stabilized acylated insulin analogues | NOVO NORDISK A/S (DK) | 2019-04-16 | — | — | US | disclosed |
| US-20100120054-A1 | MONOMERIC AND POLYMERIC LINKERS USEFUL FOR CONJUGATING BIOLOGICAL MOLECULES AND OTHER SUBSTANCES | DAKO DENMARK APS (DK) | 2010-05-13 | — | — | US | disclosed |
| US-20100055761-A1 | METHODS, COMPOSITIONS, AND KITS FOR THE SELECTIVE ACTIVATION OF PROTOXINS THROUGH COMBINATORAL TARGETING | THE GENERAL HOSPITAL CORPORATION (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100055761-A1 | METHODS, COMPOSITIONS, AND KITS FOR THE SELECTIVE ACTIVATION OF PROTOXINS THROUGH COMBINATORAL TARGETING | THE GENERAL HOSPITAL CORPORATION (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100055761-A1 | METHODS, COMPOSITIONS, AND KITS FOR THE SELECTIVE ACTIVATION OF PROTOXINS THROUGH COMBINATORAL TARGETING | THE GENERAL HOSPITAL CORPORATION (US) | 2010-03-04 | — | — | US | disclosed |
| WO-2009115469-A1 | PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES | NOVO NORDISK A/S (DK) | 2009-09-24 | — | — | WO | disclosed |
| EP-2046375-A2 | METHODS, COMPOSITIONS, AND KITS FOR THE SELECTIVE ACTIVATION OF PROTOXINS THROUGH COMBINATORIAL TARGETING | The General Hospital Corporation (US) | 2009-04-15 | — | — | EP | disclosed |
| WO-2009022006-A1 | INSULINS WITH AN ACYL MOIETY COMPRISING REPEATING UNITS OF ALKYLENE GLYCOL CONTAINING AMINO ACIDS | NOVO NORDISK A/S (DK) | 2009-02-19 | — | — | WO | disclosed |
| EP-1907592-A2 | MONOMERIC AND POLYMERIC LINKERS USEFUL FOR CONJUGATING BIOLOGICAL MOLECULES AND OTHER SUBSTANCES | Dako Denmark A/S (DK) | 2008-04-09 | — | — | EP | disclosed |
| WO-2008011157-A2 | METHODS, COMPOSITIONS, AND KITS FOR THE SELECTIVE ACTIVATION OF PROTOXINS THROUGH COMBINATORIAL TARGETING | THE GENERAL HOSPITAL CORPORATION (US) | 2008-01-24 | — | — | WO | disclosed |
| WO-2007015168-A2 | MONOMERIC AND POLYMERIC LINKERS USEFUL FOR CONJUGATING BIOLOGICAL MOLECULES AND OTHER SUBSTANCES | DAKO DENMARK A/S (US) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230270867-A1 | CONJUGATE IN WHICH FL118 DRUG IS LINKED TO ACID-SENSITIVE LINKER, AND IMMUNOCONJUGATE USING SAME | SLC46A1, SLC47A1, FOLR1 | GLP1R 2794/4885SMN1; SMN2 4568/4885MEN1 1030/4885 |
| US-20210139548-A1 | NPY2 RECEPTOR AGONISTS | NPY2R, NPY1R, NPY5R | GLP1R 6/4885SMN1; SMN2 1118/4885MEN1 1347/4885 |
| US-20240150431-A1 | MHC Multimers, Methods for Their Generation, Labeling and Use | MICA, CD74, HLA-DRB1 | GLP1R 4718/4885SMN1; SMN2 2853/4885MEN1 2127/4885 |
| US-20230340039-A1 | NPY2 RECEPTOR AGONISTS | NPY2R, NPY1R, NPY5R | GLP1R 6/4885SMN1; SMN2 1118/4885MEN1 1347/4885 |
| US-20190112348-A1 | PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES | IAPP, IDE, LIPE | GLP1R 84/4885SMN1; SMN2 1083/4885MEN1 535/4885 |
| US-10259856-B2 | Protease stabilized acylated insulin analogues | IAPP, IDE, LIPE | GLP1R 54/4885SMN1; SMN2 1218/4885MEN1 560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.